That’s because conventional pharma R&D is experiencing a continuing downward trend in its productivity, with the returns on the many billions the industry spends every year diminishing rapidly.

In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent ...

On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

We are familiar with the industry noise around falling productivity and return on investment in pharma R&D. We are less familiar with hearing the call of the small and medium-sized enterprise (SME ...

The top 20 pharma companies are focusing on novel drugs, innovative dealmaking and playing to their strengths to bolster R&D ...

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including ...

The boss of US pharmaceutical giant Eli Lilly has told the BBC there is no looking back from Donald Trump's decision to ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020 ...

Deloitte, in a series of annual reports on "Measuring the return from pharmaceutical innovation," in collaboration with other member firms, has provided insights into the state of biopharma R&D ...